![](/img/cover-not-exists.png)
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase
Badar, Talha, Kantarjian, Hagop M., Ravandi, Farhad, Jabbour, Elias, Borthakur, Gautam, Cortes, Jorge E., Pemmaraju, Naveen, Pierce, Sherry R., Newberry, Kate J., Daver, Naval, Verstovsek, SrdanLanguage:
english
Journal:
Leukemia Research
DOI:
10.1016/j.leukres.2015.06.001
Date:
June, 2015
File:
PDF, 1.03 MB
english, 2015